抗凝血酵素市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、原料、類型、地區和競爭格局分類，2021-2031年

全球抗凝血酶市場預計將從 2025 年的 7.9311 億美元成長到 2031 年的 10.8243 億美元，複合年成長率為 5.32%。

抗凝血酶是一種在肝臟中產生的重要糖蛋白，它透過中和凝血系統中的絲胺酸蛋白酶（如凝血酶和Xa因子）發揮主要的天然抗凝血作用。市場成長的主要促進因素包括遺傳性抗凝血酶缺乏症診斷準確性的提高，以及有效抗凝血治療在心肺體外迴圈等複雜外科手術中日益重要的作用。標準治療的限制凸顯了開發專用治療方法的緊迫性。根據國際血栓與止血學會2024年發布的註冊數據，58.6%的遺傳性抗凝血酶缺乏症患者儘管接受了常規抗凝血治療，但仍出現血栓症復發，這凸顯了臨床上對專用抗凝血酶替代產品的需求。

然而，血漿衍生療法的高昂成本和有限的供應量阻礙了市場擴張，並限制了預算緊張的醫療體系的可及性。抗凝血酶的生產嚴重依賴人類血漿，而這個過程又受到供體數量和嚴格安全通訊協定的極大限制。這種對波動性生物原料的依賴造成了供應鏈的脆弱性，推高了生產成本，最終限制了其在發展中地區的市場滲透。在這些地區，由於財政拮据，醫療機構不得不依賴其他價格較低廉的標準抗凝血劑。

市場促進因素

全球靜脈血栓栓塞症(VTE) 和凝血障礙發生率的上升是推動市場成長的主要催化劑，因此亟需針對高風險族群採取強力的治療性介入。血栓事件的全球性增加，尤其是在遺傳性抗凝血酶缺乏症患者以及接受複雜手術且標準肝素療效不佳的患者中，正推動對特殊替代療法的需求激增。這種不斷成長的臨床需求在主要企業的財務表現中得到了清晰的體現。例如，Griffols 公司在 2025 年 2 月公佈，其生物製藥部門 2024 年第四季的銷售額成長了 15.1%，這顯然與全球對血漿蛋白的強勁需求密切相關。

同時，血漿來源抗凝血酶濃縮物的供應日益穩定，以往的供應鏈問題得到解決，確保患者能可靠地獲得所需藥物。市場穩定取決於人血漿的高效收集和分離，主要行業參與者正在最佳化營運並擴大相關領域的產能。 Kedrion BioPharma 2025 年 4 月公佈的年銷售額為 15.78 億歐元，較去年同期成長 10%，主要得益於其血漿衍生產品組合的成長。嚴格的安全標準保障了永續的供應，從而支撐了這一成長。 2025 年 2 月，血漿蛋白治療協會指出，捐血中不利事件的發生率僅為 0.16%，並確認了維持抗凝血酵素生產所需基本捐血者族群的安全通訊協定。

市場挑戰

全球抗凝血酶市場面臨的主要障礙在於其對人類血漿分餾的依賴。血漿衍生療法依賴有限的生物資源，難以快速擴大規模以滿足日益成長的臨床需求。此外，該行業對特定採集區域的依賴進一步加劇了這一限制，導致供應鏈脆弱性。根據血漿蛋白治療協會 (PPTA) 2025 年的數據，全球超過 63% 的用於生產的血漿將來自北美，凸顯了原料的嚴重地域集中。因此，這個主要供應區域的任何中斷都將立即影響全球供應，威脅產品供應的穩定性並限制商機。

此外，為確保病毒安全性和產品純度，複雜的生產流程會產生高昂的營運成本。這些成本導致價格上漲，限制了產品在對成本敏感的醫療保健市場的普及。在預算有限的發展中地區，醫療機構往往選擇成本較低的特異性抗凝血劑，而非專業的抗凝血酶療法。這種經濟壁壘直接阻礙了市場滲透，抑制了抗凝血酶療法在新興經濟體的廣泛應用，從而限制了該市場的整體全球成長潛力。

市場趨勢

體外膜氧合（ECMO）通訊協定的日益普及正在改變市場需求。臨床醫師經常選擇抗凝血酵素替代療法來治療嚴重患者的肝素抗性。在長時間的體外循環支持過程中，天然抗凝血酵素會被迅速消耗，因此外源性補充對於維持循環通暢性和預防危險的血栓症形成至關重要，而標準抗凝血療法往往不足以達到此目的。這種與高階生命支持的整合使得治療性抗凝血酶的消耗量與機械循環支持裝置的使用量之間形成了直接關聯。體外生命支持系統（ELSO）報告稱，到2025年4月，全球累積註冊量將達到245,291台，顯示對可靠的輔助抗凝血治療的需求呈強勁上升趨勢。

同時，市場正拓展其臨床應用，將抗凝血酶應用於敗血症和創傷的治療。抗凝血酵素被定位為一種雙效療法，利用其抗發炎特性來控制膿毒性敗血性休克的凝血障礙。相關人員正積極尋求擴大其在瀰漫性血管內凝血（DIC）治療中的適應症，旨在將這種生物製藥從一種小眾孤兒藥提升為主流重症監護療法。這項策略旨在滿足巨大的未滿足需求。正如全球敗血症聯盟在2025年7月指出的那樣，敗血症約佔全球死亡人數的五分之一，這意味著龐大的患者群體，為血漿衍生療法的市場拓展提供了巨大的潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗凝血酵素市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按應用領域（治療、診斷、研究、其他）
  • 來源（人類來源、基因改造山羊乳來源、其他）
  • 依類型（抗凝血劑、抗血小板藥物、溶栓藥物）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美抗凝血酵素市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲抗凝血酵素市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗凝血酵素市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲抗凝血酵素市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲抗凝血酵素市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球抗凝血酵素市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Grifols, SA
• Takeda Pharmaceutical Company Limited
• Octapharma Brasil Ltda.
• LFB USA, Inc.
• Endpoint Health, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• BioCare, Inc.
• F. Hoffmann-La Roche Ltd
• Kedrion SpA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Antithrombin Market is projected to expand from USD 793.11 Million in 2025 to USD 1082.43 Million by 2031, registering a CAGR of 5.32%. As a vital liver-produced glycoprotein, antithrombin acts as a key natural anticoagulant by neutralizing serine proteases like thrombin and Factor Xa within the coagulation system. Market growth is largely driven by improved diagnosis of hereditary antithrombin deficiency and the critical need for effective anticoagulation during complex surgical procedures, such as cardiopulmonary bypass operations. The urgency for specialized therapies is highlighted by the limitations of standard treatments; registry data cited by the International Society on Thrombosis and Haemostasis in 2024 revealed that recurrent thrombosis affected 58.6% of patients with hereditary deficiency despite conventional anticoagulation, emphasizing the clinical necessity for dedicated antithrombin replacement products.

However, market expansion is hindered by the significant costs and restricted availability associated with plasma-derived therapeutics, which limit access within budget-constrained healthcare systems. Antithrombin production depends heavily on human plasma fractionation, a process strictly bound by donor availability and rigorous safety protocols. This reliance on a variable biological raw material introduces supply chain vulnerabilities and drives up manufacturing costs, ultimately curbing market penetration in developing regions where financial constraints often force healthcare providers to rely on alternative, less expensive standard-of-care anticoagulants.

Market Driver

The increasing global incidence of Venous Thromboembolism (VTE) and coagulation disorders acts as a major catalyst for market growth, necessitating strong therapeutic interventions for high-risk populations. With thrombotic events rising worldwide-especially among those with hereditary antithrombin deficiency or undergoing complex surgeries where standard heparin is inadequate-the demand for specialized replacement therapies has surged. This elevated clinical need is evident in the financial results of leading manufacturers; for instance, Grifols reported in February 2025 that its Biopharma unit saw a 15.1% revenue increase in the fourth quarter of 2024, a performance the company explicitly linked to robust global demand for plasma proteins.

Concurrently, the market is benefiting from the improved availability of plasma-derived antithrombin concentrates, which is addressing past supply chain issues and enabling reliable patient access. Market stability depends on efficient human plasma collection and fractionation, areas where key industry players have optimized operations and expanded capacity. Reflecting this progress, Kedrion Biopharma reported in April 2025 a fiscal year turnover of 1.578 billion Euros-a 10% increase driven by its plasma-derived portfolio. This growth is supported by strict safety standards that ensure a sustainable supply; the Plasma Protein Therapeutics Association noted in February 2025 that adverse events occur in only 0.16% of donations, confirming the safety protocols necessary to maintain the donor base essential for antithrombin production.

Market Challenge

A significant obstacle to the Global Antithrombin Market is its reliance on human plasma fractionation, as plasma-derived therapies depend on a finite biological resource that cannot be rapidly scaled to match rising clinical needs. This limitation is exacerbated by the industry's dependence on specific collection regions, leading to supply chain fragility. According to 2025 data from the Plasma Protein Therapeutics Association, North America provided over 63% of the global plasma utilized for manufacturing, highlighting a severe geographic concentration of raw material. Consequently, any interruption in this primary source region immediately affects global availability, threatening consistent product delivery and restricting revenue opportunities.

Furthermore, the intricate manufacturing processes necessary to guarantee viral safety and product purity involve high operational costs. These expenses translate into elevated pricing structures that restrict product accessibility in cost-sensitive healthcare markets. In developing regions with limited budgets, medical providers frequently opt for lower-cost, non-specific anticoagulants instead of specialized antithrombin treatments. This economic barrier directly hinders market penetration and blocks the widespread adoption of antithrombin therapies in emerging economies, effectively limiting the market's overall global growth potential.

Market Trends

The increasing use of Extracorporeal Membrane Oxygenation (ECMO) protocols is altering market demand, as clinicians frequently turn to antithrombin supplementation to manage heparin resistance in critically ill patients. Standard anticoagulation often proves insufficient during prolonged extracorporeal support because natural antithrombin is rapidly consumed, requiring exogenous replacement to maintain circuit patency and prevent dangerous thrombosis. This integration into advanced life support creates a direct link between therapeutic consumption and the rising use of mechanical circulatory support; the Extracorporeal Life Support Organization reported in April 2025 that cumulative global registry volume hit 245,291 ECMO runs, demonstrating a strong upward trend that requires reliable adjunct anticoagulation.

Simultaneously, the market is expanding its clinical scope into sepsis and trauma care, positioning antithrombin as a dual-action therapy that utilizes its anti-inflammatory properties to manage coagulopathy in septic shock. Industry stakeholders are actively seeking label expansions to treat disseminated intravascular coagulation, aiming to elevate the biologic from a niche orphan drug to a mainstream critical care treatment. This strategy addresses a massive unmet medical need; as highlighted by the Global Sepsis Alliance in July 2025, sepsis causes approximately one in five deaths worldwide, representing a vast patient population that could significantly increase the addressable market for plasma-derived therapies.

Key Market Players

• Grifols, S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma Brasil Ltda.
• LFB USA, Inc.
• Endpoint Health, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• BioCare, Inc.
• F. Hoffmann-La Roche Ltd
• Kedrion S.p.A

Report Scope

In this report, the Global Antithrombin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antithrombin Market, By Usage

• Therapeutics
• Diagnostics
• Research
• Others

Antithrombin Market, By Source

• Human
• Recombinant Goat Milk
• Others

Antithrombin Market, By Type

• Anticoagulant
• Antiplatelet
• Thrombolytic Drugs

Antithrombin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antithrombin Market.

Available Customizations:

Global Antithrombin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antithrombin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Usage (Therapeutics, Diagnostics, Research, Others)
  • 5.2.2. By Source (Human, Recombinant Goat Milk, Others)
  • 5.2.3. By Type (Anticoagulant, Antiplatelet, Thrombolytic Drugs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Antithrombin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Usage
  • 6.2.2. By Source
  • 6.2.3. By Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antithrombin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Usage
      • 6.3.1.2.2. By Source
      • 6.3.1.2.3. By Type
  • 6.3.2. Canada Antithrombin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Usage
      • 6.3.2.2.2. By Source
      • 6.3.2.2.3. By Type
  • 6.3.3. Mexico Antithrombin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Usage
      • 6.3.3.2.2. By Source
      • 6.3.3.2.3. By Type

7. Europe Antithrombin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Usage
  • 7.2.2. By Source
  • 7.2.3. By Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antithrombin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Usage
      • 7.3.1.2.2. By Source
      • 7.3.1.2.3. By Type
  • 7.3.2. France Antithrombin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Usage
      • 7.3.2.2.2. By Source
      • 7.3.2.2.3. By Type
  • 7.3.3. United Kingdom Antithrombin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Usage
      • 7.3.3.2.2. By Source
      • 7.3.3.2.3. By Type
  • 7.3.4. Italy Antithrombin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Usage
      • 7.3.4.2.2. By Source
      • 7.3.4.2.3. By Type
  • 7.3.5. Spain Antithrombin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Usage
      • 7.3.5.2.2. By Source
      • 7.3.5.2.3. By Type

8. Asia Pacific Antithrombin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Usage
  • 8.2.2. By Source
  • 8.2.3. By Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antithrombin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Usage
      • 8.3.1.2.2. By Source
      • 8.3.1.2.3. By Type
  • 8.3.2. India Antithrombin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Usage
      • 8.3.2.2.2. By Source
      • 8.3.2.2.3. By Type
  • 8.3.3. Japan Antithrombin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Usage
      • 8.3.3.2.2. By Source
      • 8.3.3.2.3. By Type
  • 8.3.4. South Korea Antithrombin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Usage
      • 8.3.4.2.2. By Source
      • 8.3.4.2.3. By Type
  • 8.3.5. Australia Antithrombin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Usage
      • 8.3.5.2.2. By Source
      • 8.3.5.2.3. By Type

9. Middle East & Africa Antithrombin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Usage
  • 9.2.2. By Source
  • 9.2.3. By Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antithrombin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Usage
      • 9.3.1.2.2. By Source
      • 9.3.1.2.3. By Type
  • 9.3.2. UAE Antithrombin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Usage
      • 9.3.2.2.2. By Source
      • 9.3.2.2.3. By Type
  • 9.3.3. South Africa Antithrombin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Usage
      • 9.3.3.2.2. By Source
      • 9.3.3.2.3. By Type

10. South America Antithrombin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Usage
  • 10.2.2. By Source
  • 10.2.3. By Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antithrombin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Usage
      • 10.3.1.2.2. By Source
      • 10.3.1.2.3. By Type
  • 10.3.2. Colombia Antithrombin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Usage
      • 10.3.2.2.2. By Source
      • 10.3.2.2.3. By Type
  • 10.3.3. Argentina Antithrombin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Usage
      • 10.3.3.2.2. By Source
      • 10.3.3.2.3. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antithrombin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Grifols, S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Takeda Pharmaceutical Company Limited
• 15.3. Octapharma Brasil Ltda.
• 15.4. LFB USA, Inc.
• 15.5. Endpoint Health, Inc.
• 15.6. Siemens Healthineers AG
• 15.7. Thermo Fisher Scientific Inc
• 15.8. BioCare, Inc.
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. Kedrion S.p.A

16. Strategic Recommendations

17. About Us & Disclaimer